Grifols, S.A. (GIFOF)
| Market Cap | 7.61B +1.9% |
| Revenue (ttm) | 8.63B +1.0% |
| Net Income | 555.30M +31.2% |
| EPS | 0.81 |
| Shares Out | n/a |
| PE Ratio | 10.98 |
| Forward PE | 9.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 149 |
| Open | 8.85 |
| Previous Close | 7.29 |
| Day's Range | 8.85 - 8.85 |
| 52-Week Range | 7.08 - 8.85 |
| Beta | 1.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About Grifols
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as wel... [Read more]
Financial Performance
In 2025, Grifols's revenue was 7.52 billion, an increase of 4.33% compared to the previous year's 7.21 billion. Earnings were 402.00 million, an increase of 156.05%.
Financial numbers in EUR Financial StatementsNews
Grifols Q3 Net Profit Rises, Revenue Up 8.4%; On Track To Meet 2026 Guidance
(RTTNews) - Grifols (GRFS, GRF.MC, 1GRF.MI) reported that its net profit in the third quarter increased 27.9% compared with the prior-year quarter to 162 million euros. Adjusted EBITDA grew 9.8% cc to...
Grifols (GRFS) Q3 2026 Earnings Call Transcript
Biopharma revenue grew 10.3% as net leverage fell below 4.0x.
Grifols Q3 Earnings Call Highlights
Grifols NASDAQ: GRFS reported third-quarter 2026 results marked by revenue growth, expanding profitability, stronger free cash flow and lower leverage, while management reiterated its full-year financ...
Grifols Earnings Call Transcript: Q3 2026
Q3 revenue rose 8.4% at constant currency and adjusted EBITDA grew 9.8%, with 9M free cash flow at EUR 298m and leverage below 4x. Guidance remains on track, while China albumin weakness and Q4 comparisons temper near-term growth.
Grifols Earnings release: Q3 2026
Grifols released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Grifols Slides: Q3 2026
Grifols has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Grifols price target lowered to $9 from $10 at JPMorgan
JPMorgan lowered the firm’s price target on Grifols (GRFS) to $9 from $10 and keeps a Neutral rating on the shares.
Plasma donation company Grifols begins phased reopening of centres after 2-month hiatus
Grifols is resuming operations at its Canadian clinics after temporarily shutting down all paid plasma collection in mid-August amid public scrutiny.
Grifols says Canada plasma license suspension has no impact
Spanish drugmaker Grifols said Health Canada's decision to suspend its license to collect plasma at its Taylor Avenue facility in Winnipeg had no impact on operations.
Grifols completes clinical portion of SPARTA trial
Grifols (GRFS) announced the completion of the clinical portion of SPARTA, its phase 3 outcomes study evaluating the clinical efficacy and safety of two dose regimens of Prolastin-C in patients…
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the complet...
Grifols says EXCELL Phase 3 trial timeline not ‘new development or a delay’
Grifols (GRFS) issued the following statement on the EXCELL Phase 3 trial timeline: “We have noted the recent Bloomberg article referring to the EXCELL Phase III trial timeline on ClinicalTrials.gov.
Grifols Q2 Earnings Call Highlights
Grifols NASDAQ: GRFS said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, im...
Grifols Earnings Call Transcript: Q2 2026
Revenue grew 2.6% in H1 2026, led by Biopharma and strong IG demand, with adjusted EBITDA up 2.4% and free cash flow improving by EUR 103 million year-over-year. Albumin in China stabilized, diagnostics advanced with new launches, and the company remains on track for its 2026 guidance.
Grifols Quarterly report: Q2 2026
Grifols has published its Q2 2026 quarterly earnings report on July 28, 2026.
Grifols Slides: Q2 2026
Grifols has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
Grifols Earnings release: Q2 2026
Grifols released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Grifols doses first patients in two Gamunex-C trials
Grifols (GRFS) announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, Gamunex-C, an intravenou...
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the fi...
Grifols announces U.S. launch of new fibrinogen concentrate
Grifols (GRFS) announced the U.S. launch of its new fibrinogen concentrate. Approved by the FDA in December for the treatment of acute bleeding episodes in pediatric and adult patients with…
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. la...
Grifols price target lowered to EUR 10 from EUR 11 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Grifols (GRFS) to EUR 10 from EUR 11 and keeps a Hold rating on the shares.
Grifols reports Q1 adjusted EBITDA EUR 381M, up 0.8% cc
Reports Q1 total revenue EUR 1.7B, up 3.3% y/y cc. Group profit increased to EUR 73M in the first quarter, up 21.9% year-on-year. Nacho Abia, CEO of Grifols (GRFS), said:…
Grifols says Q1 results support FY26 guidance
11:43 EDT Grifols (GRFS) says Q1 results support FY26 guidance
Grifols Earnings Call Transcript: Q1 2026
Q1 2026 results were in line with expectations, led by strong Biopharma growth and margin expansion from plasma sourcing optimization. Financial position improved with refinancing and deleveraging, while Diagnostic and specialty proteins segments are set for renewed growth.